Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively WATERTOWN, Mass.,
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical
KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr.
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44 th Annual J.P.